Literature Collection

Integration of behavioral health care into primary care can improve health and economic outcomes. This study adapted the Behavioral Health Integration in Medical Care (BHIMC) index to the Colombian context and assessed the baseline level of behavioral health integration in a sample of primary care organizations. The BHIMC was able to detect the capacity to provide integrated behavioral care in Colombian settings. Results indicate a minimal to partial integration level across all sites, and that it is possible to measure the degree of integrated care capacity and identify improvement areas for better behavioral health care provision.

BACKGROUND: Integrated care addresses the fragmentation of patient health services and potentially improves the experience of care, reduces healthcare costs, and improves health outcomes. This study assessed the improvements in mental health and physical health outcomes among patients living with mental health challenges and treated in an integrated care setting. METHODS: The longitudinal retrospective cohort study evaluated anxiety (GAD-7), depression (PHQ-9), systolic blood pressure, and glycated hemoglobin levels from baseline to the next three assessments recorded from October 1, 2018, to December 31, 2023. RESULTS: At baseline, 239 participants responded to mental health outcome measures, 344 to systolic blood pressure, and 164 to glycated hemoglobin level. The Generalized Estimating Equations analysis showed an improvement in GAD-7 (-1.28 [95% CI, -1.71 to -0.85]) and PHQ-9 (-1.37 [95% CI, -1.73 to -0.92]) scores in successive assessments. The physical health outcomes (Systolic blood pressure (-0.004 [95% CI, -1.34 to 1.35]) and glycated hemoglobin (0.04 [95% CI, -0.07 to 0.15])) remained stable. CONCLUSION: This study demonstrates that patients with mental health challenges treated in integrated care experience improvements in depression and anxiety symptoms, with stable physical health outcomes.

OBJECTIVE: Racemic ketamine intravenous treatments (KIT) are widely used in community clinics for treatment resistant depression (TRD), but we lack studies on symptom improvement during standardized delivery to clinically complex patients with TRD. We aimed to assess depression symptom change for patients receiving standardized KIT for TRD in a large integrated health care delivery system relative to similar patients receiving standard medication management. METHODS: In this retrospective cohort study (n = 570), depression symptom change measured by the 9-item Patient Health Questionnaire (PHQ-9) was examined in 143 adults with TRD receiving 0.5mg/kg 40-minute KIT infusion twice weekly for 3 weeks from 01/01/2018 to 12/31/2022 and 427 contemporaneous patients with medication management (MM) matched on variables including sex, race, age, and baseline depression symptom score. We excluded patients with major neurocognitive disorder, schizophrenia, or pregnancy. RESULTS: The KIT group was more likely to achieve depression response (PHQ-9 reduction >50 %) compared to MM (adjusted risk ratio [aRR]= 1.72, 95 % CI = 1.17 - 2.53; P = 0.006). The KIT group (8 % vs 5 %) was more likely to achieve depression remission (i.e. PHQ-9 < 5); however, the adjusted risk with KIT vs MM was not statistically significant. Baseline depression symptoms were associated with higher depression symptoms at follow up, as were co-occurring anxiety and personality disorders. CONCLUSIONS: KIT was significantly associated with depression response and symptom improvement compared to MM. Clinicians should consider comorbid personality disorder, anxiety disorders, and baseline depression severity as potential predictors of KIT and other treatment response in TRD.